GEHC Earnings Date: Feb 3, 2027 (Estimated) — GE HealthCare Technologies Inc.
NASDAQ · Healthcare · Health Information Services
Updated
When is GEHC's next earnings date?
GE HealthCare Technologies Inc. (GEHC) is expected to report Q4 2026 earnings on Wednesday, February 3, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.60 on revenue of $5.94B.
How did GEHC do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), GE HealthCare Technologies Inc. posted EPS of $1.34 versus the $1.20 estimate, a beat of 11.7%. Revenue was $5.51B against a $5.35B estimate. The stock's 1-day post-earnings move was +6.6%.
How much does GEHC stock move after earnings?
GEHC beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.4% (up or down) in the day after earnings.
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
🤖 AI Earnings Analysis
GE HealthCare’s imaging demand and record backlog support a solid quarter, with Q3 revenue of $5.5B and EPS of $1.34 beating estimates. Growth was steady rather than explosive; reaffirmed $4.80–$5.00 EPS guidance leaves margin pressure from inflation and supply constraints in focus.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | 1.20 | 1.34 | +11.67% | $5.51B | ✅ Beat | +6.62% | — | — |
| 2026-07-29 | Q2 2026 | 1.04 | 1.13 | +8.65% | $5.29B | ✅ Beat | +12.16% | +9.60% | +14.36% |
| 2026-04-29 | Q1 2026 | 1.05 | 0.99 | -5.71% | $5.13B | ❌ Miss | -13.16% | -10.88% | -8.24% |
| 2026-02-04 | Q4 2025 | 1.41 | 1.44 | +2.13% | $5.70B | ✅ Beat | +4.88% | +0.56% | -2.12% |
| 2025-10-29 | Q3 2025 | 1.05 | 1.07 | +1.90% | $5.14B | ✅ Beat | -2.55% | -6.43% | +1.54% |
| 2025-07-30 | Q2 2025 | 0.91 | 1.06 | +16.48% | $5.01B | ✅ Beat | -7.83% | -8.97% | -4.45% |
| 2025-04-30 | Q1 2025 | 0.91 | 1.01 | +10.99% | $4.78B | ✅ Beat | +3.28% | -1.47% | +5.05% |
| 2025-02-13 | Q4 2024 | 1.26 | 1.45 | +15.08% | $5.32B | ✅ Beat | +8.83% | +7.22% | -4.58% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $1.64B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| PDx | 51.6% | $846.0M | — | $645.0M | $632.0M | $729.0M | $1.54B |
| PCS | 48.4% | $793.0M | — | $827.0M | $753.0M | $778.0M | $1.55B |
By region
FY2025 · $20.63B total · annual
| Segment | Share | Revenue | YoY | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Other Countries | 45.7% | $9.43B | +5.7% | $8.92B | $9.43B |
| UNITED STATES | 44.4% | $9.17B | +6.4% | $8.62B | $9.17B |
| CHINA | 9.8% | $2.03B | -4.9% | $2.13B | $2.03B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.